Treatment Modalities for Heart Failure with Preserved Ejection Fraction (HFpEF) - Current State of Evidence and Future Perspective

2015 ◽  
Vol 06 (07) ◽  
Author(s):  
Sunny Goel Avraham Miller
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Treatment Modalities ◽  
Future Perspective ◽  
Preserved Ejection Fraction ◽  
Current State

scholarly journals Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives

2020 ◽  
Vol 6 ◽  
Author(s):  
Sebastian Rosch ◽  
Karl-Philipp Rommel ◽  
Markus Scholz ◽  
Holger Thiele ◽  
Philipp Lurz
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Future Perspective ◽  
Preserved Ejection Fraction ◽  
Cross Sectional ◽  
Reduced Ejection Fraction ◽  
Current State ◽  
Biomarker Research ◽  
Study Designs ◽  
Molecular Pathomechanisms

Heart failure with preserved ejection fraction (HFpEF) is increasing in incidence and has a higher prevalence compared with heart failure with reduced ejection fraction. So far, no effective treatment of HFpEF is available, due to its complex underlying pathophysiology and clinical heterogeneity. This article aims to provide an overview and a future perspective of transcriptomic biomarker research in HFpEF. Detailed characterisation of the HFpEF phenotype and its underlying molecular pathomechanisms may open new perspectives regarding early diagnosis, improved prognostication, new therapeutic targets and tailored therapies accounting for patient heterogeneity, which may improve quality of life. A combination of cross-sectional and longitudinal study designs with sufficiently large sample sizes are required to support this concept.

scholarly journals Recognition, Diagnosis, and Management of Heart Failure with Preserved Ejection Fraction

2018 ◽  
Vol 12 (1) ◽  
pp. 8-12
Author(s):  
Meshal Soni ◽  
Edo Y Birati
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Diagnostic Criteria ◽  
Paradigm Shift ◽  
Management Strategies ◽  
Clinical Syndrome ◽  
Treatment Modalities ◽  
Preserved Ejection Fraction ◽  
Reduced Ejection Fraction ◽  
The Common

The clinical syndrome of heart failure with preserved ejection fraction (HFpEF) is unique in terms of etiologies, diagnostic criteria, costs, and treatment modalities when compared to heart failure with reduced ejection fraction. There is an emerging paradigm shift that recognizes the clinical syndrome of HFpEF and its various phenotypes. Understanding these HFpEF phenotypes is crucial to understanding the pathophysiology of HFpEF, which in turn can further guide our management strategies. This review outlines the diagnostic criteria, introduces the common clinical phenotypes, and discusses treatments currently utilized in practice for the management of HFpEF.

scholarly journals Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction

2018 ◽  
Vol 12 ◽  
pp. 117954681775160 ◽  
Author(s):  
Shane Nanayakkara ◽  
Hitesh C Patel ◽  
David M Kaye
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Current Treatment ◽  
Treatment Modalities ◽  
Ageing Population ◽  
Preserved Ejection Fraction ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure ◽  
The Impact ◽  
Overall Mortality

Heart failure is highly prevalent with more than 50% of cases being patients with a preserved ejection fraction (HFPEF), a figure that is projected to increase due to the changing risk factor landscape, in particular the ageing population. Overall mortality is similar to patients with heart failure with reduced ejection fraction (HFREF), as are the rates of hospitalisation. Patients with HFPEF have more comorbid conditions with fewer therapeutic options available. In this review, we explore the epidemiology of hospitalisation of HFPEF, the impact of current treatment modalities, and the potential of future therapies.

scholarly journals Immunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives

2020 ◽  
Author(s):  
Elise L. Kessler ◽  
Martinus I.F.J. Oerlemans ◽  
Patricia van den Hoogen ◽  
Carmen Yap ◽  
Joost P.G. Sluijter ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Preserved Ejection Fraction ◽  
Future Perspectives ◽  
Current State

Acute heart failure with preserved ejection fraction and long-term Readmisions

2008 ◽  
Vol 7 ◽  
pp. 62-63
Author(s):  
J NUNEZ ◽  
L MAINAR ◽  
G MINANA ◽  
R ROBLES ◽  
J SANCHIS ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Acute Heart Failure ◽  
Preserved Ejection Fraction

Galectin-3 in Heart Failure – Linking Fibrosis, Remodelling and Progression

2010 ◽  
Vol 6 (2) ◽  
pp. 33 ◽  
Author(s):  
Christopher R deFilippi ◽  
G Michael Felker ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Risk Stratification ◽  
Cardiac Fibrosis ◽  
The Elderly ◽  
Preserved Ejection Fraction ◽  
Heart Failure Patients ◽  
Large Populations ◽  
Galectin 3

For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodelling that represents an intriguing link between inflammation and fibrosis. In this article we review the biology of galectin-3, recent clinical research and its application in the management of heart failure patients.

Sign in / Sign up

Export Citation Format

Share Document